Document is current
Any future updates will be listed below
-
Authors
Deng, Nan
Duzagac, Fahriye https://orcid.org/0000-0002-4130-2246
Bolivar, Ana M.
Reyes-Uribe, Laura
Taggart, Melissa W.
Thirumurthi, Selvi
Ricciardiello, Luigi
Lynch, Patrick M.
Nancy You, Y. https://orcid.org/0000-0002-5294-288X
Kopetz, Scott https://orcid.org/0000-0001-9647-3416
Scheet, Paul https://orcid.org/0000-0002-5173-7497
Lizee, Gregory A. https://orcid.org/0000-0003-4449-7461
Reuben, Alexandre https://orcid.org/0000-0003-4510-0382
Marin, Fatima
Pineda, Marta https://orcid.org/0000-0002-5403-5845
Sinha, Krishna M.
Bansal, Ajay
Capella, Gabriel
Vilar, Eduardo https://orcid.org/0000-0001-6404-3761
- License Information
-
More Information
Article History
Received: 30 January 2025
Accepted: 17 March 2026
First Online: 3 April 2026
Competing interests
: Eduardo Vilar (EV) had a consulting or advisory role with Janssen Research and Development, Recursion Pharma, Nouscom, Abbvie, Moderna, Permanence Bio and Parabilis. EV has received research support from Janssen Research and Development and Nouscom. EV has equity in Permanence Bio. The remaining authors declare no competing interests.
